|
Suzuken Co., Ltd. (9987.t) DCF -Bewertung
JP | Healthcare | Medical - Distribution | JPX
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Suzuken Co., Ltd. (9987.T) Bundle
Vereinfachen Sie die Bewertung der Suzuzuken Co., Ltd. (9987T) mit diesem anpassbaren DCF -Taschenrechner! Mit Real Suzuken Co., Ltd. (9987t) Finanzdaten und einstellbaren Prognoseeingaben können Sie Szenarien testen und Suzuken Co., Ltd. (9987t) in Minuten aufdecken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,213,532.0 | 2,128,478.0 | 2,232,774.0 | 2,314,828.0 | 2,386,493.0 | 2,433,199.4 | 2,480,819.9 | 2,529,372.4 | 2,578,875.2 | 2,629,346.7 |
| Revenue Growth, % | 0 | -3.84 | 4.9 | 3.67 | 3.1 | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 |
| EBITDA | 53,287.0 | 22,916.0 | 32,554.0 | 39,480.0 | 51,579.0 | 42,867.1 | 43,706.0 | 44,561.4 | 45,433.5 | 46,322.7 |
| EBITDA, % | 2.41 | 1.08 | 1.46 | 1.71 | 2.16 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 |
| Depreciation | 11,426.0 | 10,308.0 | 10,019.0 | 8,844.0 | 8,744.0 | 10,694.7 | 10,904.0 | 11,117.4 | 11,335.0 | 11,556.8 |
| Depreciation, % | 0.51619 | 0.48429 | 0.44872 | 0.38206 | 0.3664 | 0.43953 | 0.43953 | 0.43953 | 0.43953 | 0.43953 |
| EBIT | 41,861.0 | 12,608.0 | 22,535.0 | 30,636.0 | 42,835.0 | 32,172.4 | 32,802.1 | 33,444.0 | 34,098.6 | 34,765.9 |
| EBIT, % | 1.89 | 0.59235 | 1.01 | 1.32 | 1.79 | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 |
| Total Cash | 211,629.0 | 212,120.0 | 201,463.0 | 192,703.0 | 242,112.0 | 228,814.7 | 233,292.9 | 237,858.7 | 242,513.9 | 247,260.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 485,763.0 | 489,797.0 | 516,455.0 | 519,817.0 | .0 | 440,620.2 | 449,243.6 | 458,035.8 | 467,000.1 | 476,139.8 |
| Account Receivables, % | 21.95 | 23.01 | 23.13 | 22.46 | 0 | 18.11 | 18.11 | 18.11 | 18.11 | 18.11 |
| Inventories | 139,726.0 | 132,618.0 | 137,987.0 | 139,368.0 | 142,356.0 | 149,441.3 | 152,366.1 | 155,348.0 | 158,388.4 | 161,488.2 |
| Inventories, % | 6.31 | 6.23 | 6.18 | 6.02 | 5.97 | 6.14 | 6.14 | 6.14 | 6.14 | 6.14 |
| Accounts Payable | 644,161.0 | 643,769.0 | 664,280.0 | 666,515.0 | 744,183.0 | 725,455.0 | 739,653.0 | 754,128.8 | 768,888.0 | 783,936.0 |
| Accounts Payable, % | 29.1 | 30.25 | 29.75 | 28.79 | 31.18 | 29.81 | 29.81 | 29.81 | 29.81 | 29.81 |
| Capital Expenditure | -11,698.0 | -7,864.0 | -14,292.0 | -17,742.0 | -15,640.0 | -14,403.8 | -14,685.7 | -14,973.1 | -15,266.2 | -15,564.9 |
| Capital Expenditure, % | -0.52848 | -0.36947 | -0.6401 | -0.76645 | -0.65535 | -0.59197 | -0.59197 | -0.59197 | -0.59197 | -0.59197 |
| Tax Rate, % | 32.19 | 32.19 | 32.19 | 32.19 | 32.19 | 32.19 | 32.19 | 32.19 | 32.19 | 32.19 |
| EBITAT | 28,248.8 | 7,927.1 | 14,425.6 | 20,372.9 | 29,044.5 | 21,148.6 | 21,562.5 | 21,984.5 | 22,414.7 | 22,853.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 46,648.8 | 13,053.1 | -1,363.4 | 8,966.9 | 616,645.5 | -448,994.1 | 20,430.5 | 20,830.4 | 21,238.1 | 21,653.7 |
| WACC, % | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -356,104.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 22,087 | |||||||||
| Terminal Value | 666,470 | |||||||||
| Present Terminal Value | 514,458 | |||||||||
| Enterprise Value | 158,354 | |||||||||
| Net Debt | -181,830 | |||||||||
| Equity Value | 340,184 | |||||||||
| Diluted Shares Outstanding, MM | 81 | |||||||||
| Equity Value Per Share | 4,195.71 |
What You Will Receive
- Authentic SUZUKEN Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are automatically calculated.
- Scenario Simulation: Evaluate various scenarios to assess Suzuken's future performance.
- User-Friendly Interface: Designed for professionals but user-friendly for novices.
Key Features
- Comprehensive Suzuken Financials: Includes historical data and future projections for Suzuken Co., Ltd. (9987T).
- Customizable Assumptions: Tailor revenue growth, profit margins, WACC, tax rates, and capital expenditures to suit your analysis.
- Interactive Valuation Model: Automatically calculates Net Present Value (NPV) and intrinsic value based on your customized inputs.
- Scenario Analysis: Develop multiple forecasting scenarios to evaluate various valuation possibilities.
- Intuitive Interface: Designed for ease of use, catering to both novices and seasoned professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Suzuken Co., Ltd.'s (9987T) pre-filled financial data and forecasts.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for informed investment decisions.
Why Opt for This Calculator?
- Designed for Experts: A sophisticated tool utilized by financial analysts, executives, and consultants.
- Accurate Data: Suzuken Co., Ltd.'s (9987T) historical and projected financials are pre-loaded for precision.
- Scenario Analysis: Effortlessly model various forecasts and assumptions.
- Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Comprehensive step-by-step guidance to navigate the process smoothly.
Who Can Benefit from This Product?
- Students in Healthcare Management: Explore healthcare valuation methodologies and apply them with real-world data.
- Researchers: Utilize industry benchmarks in your studies or academic papers.
- Investors: Validate your investment hypotheses and evaluate valuation results for Suzuken Co., Ltd. (9987T).
- Financial Analysts: Optimize your analyses with a ready-to-use, customizable DCF model.
- Healthcare Entrepreneurs: Understand the evaluation processes used for large healthcare companies like Suzuken Co., Ltd. (9987T).
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Suzuken Co., Ltd. (9987T), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A specific sheet for calculating the Weighted Average Cost of Capital (WACC), featuring key parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that present intrinsic value along with comprehensive calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to enhance analysis.
- Key Ratios: Metrics covering profitability, leverage, and efficiency ratios relevant to Suzuken Co., Ltd. (9987T).
- Dashboard and Charts: A visual overview of valuation outputs and assumptions designed for easy analysis of results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.